The Food and Drug Administration (FDA) has approved Filkri ® (filgrastim-laha), a biosimilar to Neupogen ® (filgrastim). Filkri, a leukocyte growth factor, is approved to: ...

The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...

The FDA approves biosimilar chemo infection risk treatment Filkri for cancer patients, expanding granulocyte colony-stimulating factor options.

The speed and extent of biosimilar penetration differ across provider types. Provider awareness and incentives are significantly associated with biosimilar uptake. ABSTRACTObjectives: To identify ...

Please provide your email address to receive an email when new articles are posted on . There was a substantial uptake in the use of alternative filgrastim products, including its biosimilar ...

The US Food and Drug Administration (FDA) has approved filgrastim-aafil (Nivestym, Pfizer), a biosimilar filgrastim (Neupogen, Amgen), making it the second biosimilar for this agent in the United ...

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings. Biosimilars ...

Filgrastim (Neupogen®, granulocyte-colony stimulating factor) is among the few countermeasures recommended for management of patients in the event of lethal total-body irradiation. Despite the ...

Please provide your email address to receive an email when new articles are posted on . The use of biosimilar biologics filgrastim-sndz and tbo-filgrastim increased substantially among Medicare ...